Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis (Q38468524)

3 September 2017

0 references

1 reference

title

Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis (English)

1 reference

3 September 2017

0 references

0 references

1 reference

1 reference

1 reference

Nur Johari

0 references

Janey Messina

0 references

Nathan Ford

object named as

Nathan Ford

1 reference

3 September 2017

V Bhargavi Rao

1 reference

3 September 2017

Philipp du Cros

1 reference

3 September 2017

Janey Messina

1 reference

3 September 2017

Graham S Cooke

1 reference

3 September 2017

language of work or name

English

0 references

publication date

5 May 2015

1 reference

Lancet Infectious Diseases

3 September 2017

published in

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

page(s)

819-824

1 reference

Evolving epidemiology of hepatitis C virus

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Hepatitis C therapy update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Hepatitis C drugs not reaching poor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Treatment outcomes of treatment-naïve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

A basic introduction to fixed-effect and random-effects models for meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Transformations Related to the Angular and the Square Root

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Two-sided confidence intervals for the single proportion: comparison of seven methods

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

HBV, HCV co-infection among blood donors in Nigeria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Outbreak of hepatitis C among patients admitted to the Department of Gynecology, Obstetrics, and Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Transmission of hepatitis C from a midwife to a patient through non-exposure prone procedures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

Prevalence of hepatitis C infection and risk factors in hospitalized diabetic patients: results of a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900006-7

7 January 2021

10.1016/S1473-3099(15)00006-7

Identifiers

DOI

1 reference

3 September 2017

1 reference